- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02741141
A Comparative Study of the Effect of Two Partographs on the Cesarean Section Rate in Women in Spontaneous Labour (PARTODYS)
In the 2010-french perinatal survey, the overall cesarean section (CS) rate during labour was 21 % and 16% to 38% in case of dystocia.
The definition of " dystocia " is traditionally based on the research led by Friedman in the 1950's on a restricted population sample. Several studies over the last years seem to indicate that the different phases of labour are longer than originally described by Friedman.
Our current hypothesis is that the application of a new definition of dystocia would enable a more appropriate management of labour.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The main purpose of this study is to show a significant decrease of the CS rate with the use of the new partograph developed by Neal and Lowe.
Secondary purposes are
- To reduce the use of oxytocin during labour without increasing maternal or neonatal morbidity;
- To decrease immediate per-operative complications and post-operative complications associated with CS
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Strasbourg, France, 67098
- University Strasbourg Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Age ≥ 18 years
- Affiliation to a social security insurance
- Written consent given
- Singleton pregnancy
- Cephalic presentation
- ≥37 gestational weeks
- Spontaneous onset of labour
Exclusion Criteria:
- Previous cesarean section
- Induction of labour
- Intrauterine growth restriction
- In utero fetal death
- Congenital malformation
- Chorioamnionitis
- Placenta praevia
- Need for an emergency delivery (fetal heart rate abnormalities at admission)
- Contra-indication for vaginal delivery
- Patient under temporary guardianship, guardianship or judicial protection
- Patient included in another study which could interfere with the results of this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Classical partograph
Labour dystocia is diagnosed when cervical dilation is less than 1 cm per hour or after 3 hours at complete cervical dilation without engagement of the presentation.
In this case, active management of labour is started with introduction of oxytocin, artificial rupture of membranes and supportive therapy.
|
Classical partograph used as standard care
|
|
Experimental: New partograph
The second strategy is based on the partograph developped by Neal and Lowe.
An active management of labour is started when crossing the dystocia line or when there are no cervical modifications after 4 hours beyond 5 cm of cervical dilation.
In this case, active management of labour is started with introduction of oxytocin, artificial rupture of membranes and supportive therapy.
|
The partograph designed by Neal and Lowe includes an "action line" which if crossed permits an active management of labour. Eventually, the only difference between the two arms is the moment when the active management of labour is started. The oxytocin is administrated according to the department protocol. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Cesarean section rate (all causes)
Time Frame: From admission in the labour ward to the delivery (duration from 0 to 24 hours approximately)
|
From admission in the labour ward to the delivery (duration from 0 to 24 hours approximately)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
obstetrical measures associated with possible effects of both strategies on maternal and fetal outcome
Time Frame: From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
Total amount of oxytocin used (mUI)
|
From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
|
obstetrical measures associated with possible effects of both strategies on maternal and fetal outcome
Time Frame: From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
Rate of uterine hyperstimulation (%)
|
From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
|
obstetrical measures associated with possible effects of both strategies on maternal and fetal outcome
Time Frame: From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
Rate of post-partum hemorrhage (%)
|
From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
|
obstetrical measures associated with possible effects of both strategies on maternal and fetal outcome
Time Frame: From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
Rate of uterine rupture (%)
|
From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
|
obstetrical measures associated with possible effects of both strategies on maternal and fetal outcome
Time Frame: From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
Rate of retained placenta (%)
|
From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
|
obstetrical measures associated with possible effects of both strategies on maternal and fetal outcome
Time Frame: From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
Need of an artificial rupture of membranes (Y/N)
|
From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
|
obstetrical measures associated with possible effects of both strategies on maternal and fetal outcome
Time Frame: From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
Color of the amniotic fluid
|
From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
|
obstetrical measures associated with possible effects of both strategies on maternal and fetal outcome
Time Frame: From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
Duration of the first and second stages of labour
|
From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
|
obstetrical measures associated with possible effects of both strategies on maternal and fetal outcome
Time Frame: From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
Rate of vaginal delivery (spontaneous or assisted) (%)
|
From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
|
obstetrical measures associated with possible effects of both strategies on maternal and fetal outcome
Time Frame: From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
Rate of cesarean section (according to indication) (%)
|
From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
|
Maternal measures associated with possible effects of both strategies on maternal and fetal outcome
Time Frame: From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
Need for an epidural or general anaesthesia
|
From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
|
Maternal measures associated with possible effects of both strategies on maternal and fetal outcome
Time Frame: From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
Transfusion rate (%)
|
From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
|
Maternal measures associated with possible effects of both strategies on maternal and fetal outcome
Time Frame: From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
Maternal fever during labour (°C)
|
From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
|
Maternal measures associated with possible effects of both strategies on maternal and fetal outcome
Time Frame: From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
Rate of thrombo-embolic events (%)
|
From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
|
Maternal measures associated with possible effects of both strategies on maternal and fetal outcome
Time Frame: From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
Rate of third- and fourth-degree perineal tears and episiotomy (%)
|
From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
|
Maternal measures associated with possible effects of both strategies on maternal and fetal outcome
Time Frame: From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
Rate of surgical site infection, endometritis or septicemia (%)
|
From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
|
Neonatal measures associated with possible effects of both strategies on maternal and fetal outcome
Time Frame: From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
Neonatal arterial umbilical cord pH < 7,00 and/or BD > 12 mmol/L
|
From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
|
Neonatal measures associated with possible effects of both strategies on maternal and fetal outcome
Time Frame: From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
Apgar score < 7 at 5 minutes
|
From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
|
Neonatal measures associated with possible effects of both strategies on maternal and fetal outcome
Time Frame: From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
Transfer to intensive care unit rate
|
From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
|
Neonatal measures associated with possible effects of both strategies on maternal and fetal outcome
Time Frame: From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
Neonatal infection rate (%)
|
From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
|
Neonatal measures associated with possible effects of both strategies on maternal and fetal outcome
Time Frame: From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
Neonatal convulsion rate (%)
|
From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
|
Neonatal measures associated with possible effects of both strategies on maternal and fetal outcome
Time Frame: From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
Rate of neonatal deaths (%)
|
From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
|
Neonatal measures associated with possible effects of both strategies on maternal and fetal outcome
Time Frame: From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
Neonatal encephalopathy rate (or the introduction of therapeutic hypothermia)
|
From the admission in the labour ward until the dismissal from maternity (2 to 5 days)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Adrien GAUDINEAU, Strasbourg's University Hospitals
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 6225
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dystocia
-
Fenerbahce UniversityNot yet recruitingShoulder Dystocia Training Using AI-supported Flipped Learning in Midwifery EducationTurkey (Türkiye)
-
Karabuk UniversityCompleted
-
Clemens TempferCompletedShoulder DystociaGermany
-
Ain Shams Maternity HospitalCompletedCervical DystociaEgypt
-
Assistance Publique - Hôpitaux de ParisTerminated
-
Ottawa Hospital Research InstituteCanadian Institutes of Health Research (CIHR); The Ottawa Hospital; The Physicians... and other collaboratorsTerminated
-
Copenhagen University Hospital, HvidovreAarhus University Hospital; Rigshospitalet, Denmark; University of Copenhagen; University... and other collaboratorsNot yet recruitingProlonged Labor | Labor DystociaDenmark
-
Christiana Care Health ServicesCompleted
-
Ain Shams UniversityCompletedFailed Induction | Cervical DystociaEgypt
Clinical Trials on Classical partograph
-
Assiut UniversityCompleted
-
International Centre for Diarrhoeal Disease Research...Completed
-
Ankara Yildirim Beyazıt UniversityNot yet recruiting
-
Uskudar UniversityAcibadem Atakent University Hospital; Acıbadem Atunizade Hospital; Acibadem Maslak...Recruiting
-
Bursa Yüksek İhtisas Education and Research HospitalRecruitingVentilators, Mechanical | Pulmonary MedicineTurkey
-
Haramaya UnversityUniversity of Copenhagen; Leiden University Medical Center; Laerdal FoundationRecruitingObstetric Complication | Perinatal Death | Maternal Death | Stillbirth | Perinatal MorbidityEthiopia
-
Istinye UniversityNot yet recruiting
-
University College, LondonUniversity of LiverpoolTerminatedCortical DysplasiaUnited Kingdom, France, Austria, United States, Czechia, Germany, Italy, Switzerland
-
Institut Claudius RegaudCompletedVulvar Neoplasms | Skin NeoplasmsFrance
-
Assistance Publique - Hôpitaux de ParisMinistry of Health, FranceWithdrawnShock | Trauma, Nervous System | Cardiac Arrest | Respiratory Distress Syndrome | Drug Toxicity | Acute Post-trauma Stress State